BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.400
-0.060 (-4.11%)
Nov 6, 2025, 4:00 PM EST - Market closed
BioRestorative Therapies Revenue
BioRestorative Therapies had revenue of $303.30K in the quarter ending June 30, 2025, with 240.40% growth. This brings the company's revenue in the last twelve months to $605.20K, up 247.62% year-over-year. In the year 2024, BioRestorative Therapies had annual revenue of $401.00K with 175.03% growth.
Revenue (ttm)
$605.20K
Revenue Growth
+247.62%
P/S Ratio
19.29
Revenue / Employee
$55,018
Employees
11
Market Cap
12.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 401.00K | 255.20K | 175.03% |
| Dec 31, 2023 | 145.80K | 26.00K | 21.70% |
| Dec 31, 2022 | 119.80K | 73.80K | 160.43% |
| Dec 31, 2021 | 46.00K | -31.00K | -40.26% |
| Dec 31, 2020 | 77.00K | -53.00K | -40.77% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
BRTX News
- 1 day ago - BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 - GlobeNewsWire
- 10 days ago - BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market - GlobeNewsWire
- 15 days ago - BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio - GlobeNewsWire
- 22 days ago - BioRestorative Therapies to Participate in the 2025 Maxim Growth Summit - GlobeNewsWire
- 4 weeks ago - BioRestorative CEO Lance Alstodt Interviewed on “The Big Biz Show” - GlobeNewsWire
- 4 weeks ago - BioRestorative Therapies Announces $1.085 Million Registered Direct Offering Priced Above Market - GlobeNewsWire
- 3 months ago - BioRestorative Therapies, Inc. (BRTX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025 - GlobeNewsWire